Crohn Disease Clinical Trial
Official title:
Effect of Acupuncture on the Microbiota-gut-brain Axis in Crohn's Disease
NCT number | NCT06364722 |
Other study ID # | ZYS2024-02 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2015 |
Est. completion date | March 28, 2024 |
Verified date | March 2024 |
Source | Shanghai Institute of Acupuncture, Moxibustion and Meridian |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multidisciplinary techniques such as multimodal neuroimaging, microbiology, and bioinformatics were applied to study the differences in correlation characteristics between gut microbes, functional brain networks, and peripheral inflammation among patients with active Crohn's disease (CD), CD in remission, and healthy subjects.
Status | Completed |
Enrollment | 64 |
Est. completion date | March 28, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. 18 = age = 75 years, gender is not limited; 2. Disease in mildly or moderately active stage: 150 = CDAI < 450 and at least one of the following is met: serum C-reactive protein = 5 mg/L, faecal calreticulin = 250 µg/g, or endoscopic ulceration, or remission stage: CDAI < 150 and at least one of the following is met: serum C-reactive protein < 5 mg/L, faecal calreticulin < 250 µg/g, or endoscopic No ulcers; 3. Not taking or taking the following medications: mesalazine (=4 g/d and have been taking for =1 month), prednisone (=15 mg/d and have been taking for =1 month), and/or azathioprine (=1 mg/kg/d and have been taking for =3 months); 4. Those who have not used biologics within 3 months prior to study entry; 5. Those who have never received acupuncture treatment; 6. Understand, agree to participate in the study and sign an informed consent form. Exclusion Criteria: 1. Patients who have recently prepared for pregnancy or are pregnant or breastfeeding; 2. Patients with severe organic pathology; 3. Patients with confirmed psychosis; 4. Patients who are suffering from multiple diseases at the same time and taking other drugs for a long time which may affect the observation of this clinical trial; 5. Patients with severe extra-intestinal manifestations such as severe skin diseases (e.g., erythema nodosum, gangrenous pyoderma, etc.), ocular lesions (e.g., iritis, uveitis, etc.), and thromboembolic diseases; 6. Those with severe intestinal fistulae, abdominal abscesses, intestinal stenosis and intestinal obstruction, perianal lesions (perianal abscesses, etc.), gastrointestinal haemorrhage, intestinal perforation and other complications; 7. Those suffering from short bowel syndrome, those who have undergone abdominal or gastrointestinal surgery within the last six months; 8. Those who are unable to perform acupuncture due to the presence of skin diseases or defects in the area selected for acupuncture. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Shanghai Institute of Acupuncture, Moxibustion and Meridian | Fudan University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of Acupuncture on Crohn's Disease Activity Index (CDAI) | Difference in Crohn's Disease Activity Index (CDAI) from baseline at 12 weeks was used for between-group assessment. | Week 12 | |
Secondary | Effects of Acupuncture on Anxiety and Depression | Differences in Hospital Anxiety Depression Scale (HADS) scores from baseline at 12 weeks were used for between-group assessment. | Week 12 | |
Secondary | Effects of Acupuncture on Quality of Life | Differences in Inflammatory Bowel Disease Questionnaire (IBDQ) scores from baseline at 12 weeks were used for between-group assessment. | Week 12 | |
Secondary | Effect of acupuncture on intestinal inflammation | Differences in serum C-reactive protein levels and faecal calprotectin levels from baseline at 12 weeks were used for between-group assessment. | Week 12 | |
Secondary | Effects of acupuncture on gut microbiota | This includes the alpha and beta diversity of gut microbes and the abundance of flora at each level. | Week 12 | |
Secondary | Effects of acupuncture on the functional activity of brain networks | Including brain network graph theory properties, connection strength. | Week 12 | |
Secondary | Effects of acupuncture on intestinal inflammation | Including intestinal barrier function, peripheral Th1/Th17-related inflammatory factors. | Week 12 | |
Secondary | Effect of Acupuncture on Brain Imaging-Gut Microbiological Correlations | The effect of acupuncture was observed by constructing correlations between brain imaging parameters and gut microbiology and gut inflammation levels. | Week 12 | |
Secondary | Safety evaluation (number of participants with abnormal reactions to acupuncture and moxibustion treatment) | Abnormal reactions after acupuncture and moxibustion, such as bleeding, hematoma, scald, dizziness and other phenomena. | Week 12 | |
Secondary | Safety evaluation (number of participants with abnormal routine blood tests) | Routine blood tests, which mainly include the number of red blood cells, white blood cells and platelets per litre of blood. | Week 12 | |
Secondary | Safety evaluation (number of participants with abnormal Liver function tests) | Liver function tests, mainly including peripheral blood concentrations of alanine aminotransferase (U/L), glutamine aminotransferase (U/L), gamma-glutamyl transpeptidase (U/L), alkaline phosphatase (U/L), total bilirubin (µmol/L), direct bilirubin (µmol/L), indirect bilirubin (µmol/L), total protein (g/L), albumin (g/L) and globulin (g/L). | Week 12 | |
Secondary | Safety evaluation (number of participants with abnormal Renal function tests) | Renal function tests, mainly including tests of creatinine (µmol/L) and urea nitrogen (mmol/L) concentrations in peripheral blood. | Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Recruiting |
NCT05169593 -
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
|
Phase 4 | |
Recruiting |
NCT06116604 -
Early Bowel Resection for Terminal Ileal Crohn's Disease
|
||
Recruiting |
NCT05294107 -
Intestinal Organoids
|
N/A | |
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT05627128 -
A Culturally Tailored Dietary Intervention to Treat Crohn's Disease
|
N/A | |
Withdrawn |
NCT04349449 -
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
|
||
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT03058679 -
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
|
N/A | |
Completed |
NCT02871635 -
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
|
Phase 3 | |
Recruiting |
NCT04266600 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease
|
N/A | |
Recruiting |
NCT04539665 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.
|
N/A | |
Recruiting |
NCT03913572 -
Treatment of Perianal Disease Using Adipose-derived Stem Cells
|
||
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Terminated |
NCT04102111 -
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT04997733 -
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
|
Phase 3 | |
Recruiting |
NCT05906576 -
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
|
Phase 4 | |
Not yet recruiting |
NCT04502303 -
18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease
|
Phase 2 | |
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 |